179 related articles for article (PubMed ID: 36068204)
21. Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins.
Anand SP; Chen Y; Prévost J; Gasser R; Beaudoin-Bussières G; Abrams CF; Pazgier M; Finzi A
Viruses; 2020 Sep; 12(10):. PubMed ID: 33003587
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
23. Why are ACE2 binding coronavirus strains SARS-CoV/SARS-CoV-2 wild and NL63 mild?
Rawat P; Jemimah S; Ponnuswamy PK; Gromiha MM
Proteins; 2021 Apr; 89(4):389-398. PubMed ID: 33210300
[TBL] [Abstract][Full Text] [Related]
24. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
25. Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition.
Sanna V; Satta S; Hsiai T; Sechi M
Eur J Med Chem; 2022 Mar; 231():114121. PubMed ID: 35114539
[TBL] [Abstract][Full Text] [Related]
26. Targeting spike glycans to inhibit SARS-CoV2 viral entry.
Guseman AJ; Rennick LJ; Nambulli S; Roy CN; Martinez DR; Yang DT; Bhinderwala F; Vergara S; Schaefer A; Baric RS; Ambrose Z; Duprex WP; Gronenborn AM
Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2301518120. PubMed ID: 37695910
[TBL] [Abstract][Full Text] [Related]
27. Investigating the binding affinity of andrographolide against human SARS-CoV-2 spike receptor-binding domain through docking and molecular dynamics simulations.
Bhattarai A; Priyadharshini A; Emerson IA
J Biomol Struct Dyn; 2023; 41(22):13438-13453. PubMed ID: 36764825
[TBL] [Abstract][Full Text] [Related]
28. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
Lata S; Akif M
J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
[TBL] [Abstract][Full Text] [Related]
29. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
30. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
Jokinen EM; Gopinath K; Kurkinen ST; Pentikainen OT
IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1281-1289. PubMed ID: 33914685
[TBL] [Abstract][Full Text] [Related]
31. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
Verkhivker G
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
[TBL] [Abstract][Full Text] [Related]
32. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.
Williams-Noonan BJ; Todorova N; Kulkarni K; Aguilar MI; Yarovsky I
J Phys Chem B; 2021 Mar; 125(10):2533-2550. PubMed ID: 33657325
[TBL] [Abstract][Full Text] [Related]
33. The SpACE-CCM: A facile and versatile cell culture medium-based biosensor for detection of SARS-CoV-2 spike-ACE2 interaction.
Ham Y; Cho NC; Kim D; Kim JH; Jo MJ; Jeong MS; Pak BY; Lee S; Lee MK; Chi SW; Kim TD; Jeong NC; Cho S
Biosens Bioelectron; 2023 May; 227():115169. PubMed ID: 36827795
[TBL] [Abstract][Full Text] [Related]
34. Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution.
Erausquin E; Glaser F; Fernández-Recio J; López-Sagaseta J
Acta Crystallogr D Struct Biol; 2022 Sep; 78(Pt 9):1156-1170. PubMed ID: 36048155
[TBL] [Abstract][Full Text] [Related]
35. Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk.
Chen P; Wang J; Xu X; Li Y; Zhu Y; Li X; Li M; Hao P
Comput Biol Chem; 2022 Feb; 96():107613. PubMed ID: 34896769
[TBL] [Abstract][Full Text] [Related]
36. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
Basit A; Ali T; Rehman SU
J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
[TBL] [Abstract][Full Text] [Related]
37. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.
Wan Y; Shang J; Graham R; Baric RS; Li F
J Virol; 2020 Mar; 94(7):. PubMed ID: 31996437
[TBL] [Abstract][Full Text] [Related]
38. A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions.
Springstein BL; Deighan P; Grabe GJ; Hochschild A
mBio; 2021 Dec; 12(6):e0293621. PubMed ID: 34781739
[TBL] [Abstract][Full Text] [Related]
39. Exploring the Fatty Acid Binding Pocket in the SARS-CoV-2 Spike Protein - Confirmed and Potential Ligands.
Queirós-Reis L; Mesquita JR; Brancale A; Bassetto M
J Chem Inf Model; 2023 Dec; 63(23):7282-7298. PubMed ID: 37991468
[TBL] [Abstract][Full Text] [Related]
40. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
J Infect Public Health; 2021 Feb; 14(2):227-237. PubMed ID: 33493919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
